AMRX:NYE-Amneal Pharmaceuticals, Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NYE

Last Closing Price

USD 5.90

Change

+0.08 (+1.37)%

Market Cap

USD 0.85B

Volume

0.74M

Average Target Price

USD 6.75 (+14.41%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed, owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinson's disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-15 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ZTS Zoetis Inc

+2.37 (+1.45%)

USD77.46B 47.68 29.87
TAK Takeda Pharmaceutical Company ..

+0.14 (+0.82%)

USD53.74B 32.50 0.10
CTLT Catalent, Inc

+1.08 (+0.98%)

USD18.71B 60.89 27.78
ELAN Elanco Animal Health Incorpora..

+0.62 (+2.10%)

USD13.90B 144.89 153.79
TEVA Teva Pharmaceutical Industries..

-0.05 (-0.46%)

USD12.00B 872.00 16.02
BHC Bausch Health Companies Inc

+0.04 (+0.13%)

USD10.73B N/A 14.12
RDY Dr. Reddy's Laboratories Limit..

+1.05 (+1.66%)

USD10.64B 37.01 0.26
PRGO Perrigo Company plc

+0.79 (+1.96%)

USD5.39B 24.33 23.14
EBS Emergent BioSolutions Inc

N/A

USD4.00B 13.16 7.91
TARO Taro Pharmaceutical Industries..

+1.65 (+2.27%)

USD2.79B 10.60 4.58

ETFs Containing AMRX

Symbol Name Weight Mer Price(Change) Market Cap
SRLN SPDR Blackstone Senior Lo.. 0.00 % 0.70 %

+0.04 (+0.09%)

USD3.56B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 29.10% 72% C- 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.10% 72% C- 86% B
Trailing 12 Months  
Capital Gain 82.10% 67% D+ 72% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 82.10% 67% D+ 70% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -17.46% 11% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.46% 11% F 4% F
Risk Return Profile  
Volatility (Standard Deviation) 48.86% 39% F 14% F
Risk Adjusted Return -35.73% 22% F 8% F
Market Capitalization 0.85B 33% F 48% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 9.44 93% A 81% B-
Price/Book Ratio 2.92 44% F 36% F
Price / Cash Flow Ratio 2.26 44% F 74% C
EV/EBITDA 10.09 69% D+ 69% D+
Management Effectiveness  
Return on Equity 19.50% 89% B+ 87% B+
Return on Invested Capital 7.16% 67% D+ 65% D
Return on Assets 2.37% 56% F 55% F
Debt to Equity Ratio 901.92% 14% F 3% F
Technical Ratios  
Short Ratio 0.97 89% B+ 67% D+
Short Percent 3.21% 69% D+ 55% F
Beta 1.36 44% F 32% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.